Investigational drug · Phase 2
NE3107
Also called: bezisterim
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Long COVID, Parkinsons Disease (PD).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
6
Any phase or sponsor naming "NE3107"
First trial start
2025
Mar 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NE3107", any sponsor or status.
Conditions studied
As listed on its trial records.
- Long COVID
- Parkinsons Disease (PD)
Approved drugs for the same conditions: Parkinson's disease · Neurology · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "NE3107" as an intervention, largest first.
- A Phase 3 Study of NE3107 in Probable Alzheimer's DiseasePivotal-lookingCompleted
BioVie Inc.Industry
NCT04669028 · 439 participants · Start Aug 5, 2021 · Primary completion Sep 30, 2023
Drug: NE3107; Placebo · For: Alzheimer Disease
Sites: Columbus, Ohio
- NE3107 in Adults With Neurological Symptoms of Long COVIDPivotal-lookingCompleted
BioVie Inc.Industry
NCT06847191 · 203 participants · Start Apr 29, 2025 · Primary completion Aug 6, 2026
Drug: NE3107; Placebo · For: Long COVID
Sites: Palo Alto, California; San Francisco, California; Aurora, Colorado · 20 sites in all
BioVie Inc.Industry
NCT06757010 · 57 participants · Start Mar 26, 2025 · Primary completion May 1, 2026
Drug: NE3107; Placebo · For: Parkinsons Disease (PD)
Sites: Farmington Hills, Michigan; Amherst, New York; Morrisville, North Carolina · 4 sites in all
BioVie Inc.Industry
NCT05083260 · 46 participants · Start Jan 4, 2022 · Primary completion Nov 21, 2022
Drug: NE3107; placebo · For: Parkinson Disease
Sites: Englewood, Colorado; Boca Raton, Florida; Hallandale, Florida · 16 sites in all
- Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of DementiaCompleted
Neurological Associates of West Los AngelesAcademic, hospital or other
NCT05227820 · 23 participants · Start Jan 19, 2022 · Primary completion Jul 20, 2022
Drug: NE3107 · For: Alzheimer Disease
Sites: Santa Monica, California
- Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain InjuryTerminated
Neurological Associates of West Los AngelesAcademic, hospital or other
NCT05970575 · 4 participants · Start Dec 21, 2023 · Primary completion Jul 21, 2025
Drug: NE3107 · For: Traumatic Brain Injury
Sites: Santa Monica, California
Newest research
PubMed records naming it or its code names, newest first.
- Current Possible Newer Pharmacological Treatment Options for Alzheimer's Disease.
Miziak B, Pluta R, Czuczwar SJ · Int J Mol Sci 2026
- ADDRESS-LC: study protocol for a phase 2, triple-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of bezisterim (NE3107) in adults with long COVID.
Markham P, Peluso MJ, Hsiang-Yi Chou S, et al. · BMJ Open 2026
- Correction: An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease.
Reading CL, Yan J, Testa MA, et al. · Front Neurosci 2025
- An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease.
Reading CL, Yan J, Testa MA, et al. · Front Neurosci 2025
- New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer's disease.
Cao Y, Zhao LW, Chen ZX, et al. · Front Neurosci 2024
- A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias.
Haroon J, Jordan K, Mahdavi K, et al. · Medicine (Baltimore) 2024
Also in development for Long COVID
- VYD2311Phase 32 trials
Invivyd, Inc. · Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.